Loading
HOXA13 (Homeobox protein Hox-A13) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.
Sequence-specific, AT-rich binding transcription factor which is part of a developmental regulatory system that provides cells with specific positional identities on the anterior-posterior axis. Sequence-specific transcription factor which is part of a developmental regulatory system that provides cells with specific positional identities on the anterior-posterior axis.
Open Targets scores its association with cancer at 0.63 (direct and indirect evidence; datatypes literature 0.97, animal model 0.58, genetic association 0.25, somatic mutation 0.93). In OnCo, 1 product record names it (Cxbladder).
In plain words · HOXA13 (Homeobox protein Hox-A13) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.
HOXA13 (Homeobox protein Hox-A13) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.
Sequence-specific, AT-rich binding transcription factor which is part of a developmental regulatory system that provides cells with specific positional identities on the anterior-posterior axis.
No product in this corpus aims at HOXA13 yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
Tumour-associated overexpression: HPA finds the RNA cancer enhanced in cancer (Prostate Adenocarcinoma (TCGA)) and tissue enhanced in normal cervix, placenta, prostate, seminal vesicle, so the tumour and the normal tissue it comes from share the target and the medicine relies on the difference in level. HPA HOXA13: RNA tissue enhanced (cervix 21 nTPM, placenta 16 nTPM, prostate 21 nTPM); no normal tissue stained high. Distribution: no corpus cancer carries a prevalence row, threshold or catalogue link for it; Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 7 of scripts/fetch-target-specificity.ts.)
Sources: Human Protein Atlas HOXA13 tissue; Human Protein Atlas HOXA13 pathology; Open Targets ENSG00000106031 associations
First described 1989. Earliest sequence paper UniProt cites for the protein: Acampora et al, Nucleic Acids Res, 1989, "The human HOX gene family". Source.
Sources: HGNC HGNC:5102 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P31271 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000106031 (association with cancer (MONDO_0004992) 0.63; (GraphQL API, CC0))
Sequence-specific, AT-rich binding transcription factor which is part of a developmental regulatory system that provides cells with specific positional identities on the anterior-posterior axis. Sequence-specific transcription factor which is part of a developmental regulatory system that provides cells with specific positional identities on the anterior-posterior axis. Location: Nucleus (UniProt). Locus 7p15.2 (HGNC).
RNA: tissue enhanced (cervix 21 nTPM, placenta 16 nTPM, prostate 21 nTPM, seminal vesicle 22 nTPM), detected in some normal tissues.
No normal tissue stained high.
RNA cancer enhanced: Prostate Adenocarcinoma 15 pTPM.
No cancer sample stained medium or high.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"HOXA13" OR ABSTRACT:"HOXA13" OR TITLE:"homeobox A13" OR ABSTRACT:"homeobox A13" OR TITLE:"Homeobox protein Hox-A13" OR ABSTRACT:"Homeobox protein Hox-A13" OR TITLE:"HOX1J" OR ABSTRACT:"HOX1J" OR TITLE:"HOX1" OR ABSTRACT:"HOX1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about HOXA13, not a curated reading list.